newsfilter
← Latest News
GlobeNewswire·

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis